A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors
Latest Information Update: 12 Sep 2024
At a glance
- Drugs Cadonilimab (Primary) ; Paclitaxel (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Sep 2024 According to an Akeso media release, the company is going to present data from this study as a late-breaking abstract in the Proffered Paper Session at the ESMO Congress 2024 from September 13th to 17th (CEST).
- 04 May 2023 Planned End Date changed from 1 Apr 2026 to 1 Jun 2026.
- 04 May 2023 Planned primary completion date changed from 1 Apr 2026 to 1 Jun 2026.